Latest Commercialization News

Page 351 of 378
Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.
Sophie Babbage
Sophie Babbage
31 Jan 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.
Ada Torres
Ada Torres
31 Jan 2025
Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.
Ada Torres
Ada Torres
31 Jan 2025
Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.
Victor Sage
Victor Sage
31 Jan 2025
Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.
Victor Sage
Victor Sage
31 Jan 2025
Astron Corporation has made significant strides in developing its Donald Rare Earths and Mineral Sands Project, securing $14.5 million in funding and progressing towards a Final Investment Decision in 2025 amid key regulatory and operational milestones.
Maxwell Dee
Maxwell Dee
31 Jan 2025
Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.
Ada Torres
Ada Torres
31 Jan 2025
Codeifai Limited reports a sharp 59% reduction in quarterly cash burn alongside a 48% rise in cash receipts, driven by its new ConnectQR SaaS platform and a strategic review of its Material Science division.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Connexion Mobility reports a robust half-year performance with 15% revenue growth and a 43% jump in net profit, driven by product innovation and expanding dealership engagement.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Connexion Mobility Limited reported a robust 15% revenue increase and a 43% jump in profit after tax for the half-year ended December 2024, underscoring its growing foothold in automotive SaaS solutions while continuing to invest in future growth.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Metal Bank Limited reports significant progress across its Australian and MENA projects, including a strategic review of its Livingstone Gold Project and new exploration rights in Saudi Arabia and Jordan, supported by a fully subscribed $1.56 million entitlement offer.
Maxwell Dee
Maxwell Dee
31 Jan 2025